HIV-1 MN NO Fragment
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Online Inquiry
HIV-1 MN isolate was taken from a pediatric AIDS patient located in the U.S. in 1984. Since MN strain is the most representative epidemic virus in the American population, scientists studied the infectivity of a series of serum samples from children infected with HIV and MN strain. The initial serum antibody titer analysis showed that MN neutralizing antibody was not related to age, sex, CD4 cell count, p24 antigen level, collection pathway, and CDC symptom grade. This viral strain exhibits the same cytopathic effects on H9 cells as HTLV-IIIB. Also infects human neoplastic CD4+ T cells including H9, CEM, U937, Molt 3, Hela CD4+ cells, and human peripheral blood lymphocytes.
Correlation of neutralizing antibody with clinical status.
HIV-l syncytium-inhibiting antibodies have been recently correlated with better clinical outcome in HIV-l e-infected children. This also supports the concept that the humoral immune response to HIV infection plays an important role in determining the course of disease progression. The MN strain is prevalent in the United States and has been used in these studies to maximize the observed possible neutralization activity. However, if autogenous isolates are used, the expected results cannot be determined. Higher neutralizing antibody titers and their correlation with protection may be obtained, as autologous will allow for higher reactivity of type-specific antibodies. On the other hand, the selection deviation caused by virus isolation hinders the ability of autologous virus isolates to accurately express the virus spectrum in vivo. Therefore, even if autologous separation is used, the results may not be accurately reflected in the body. In addition, when isolating autologous viruses, non-neutralizing or poorly neutralizing isolates can be obtained, whether as viruses that have not yet induced antibodies or as escape mutants. This immune-selective escape mutant has been confirmed in vitro and in vivo.
Conclusion
At present, the research of HIV vaccine is still in the exploratory stage, people do not know how to achieve a successful vaccine, all the clinical research is a “conceptual trial”, which is still far from the real vaccine development. More than 20 years of research, more than 100 clinical trials, have not achieved the expected results, the main reason is that there is no clear understanding of the immune protection mechanism of HIV infection. Therefore, strengthening the basic research of HIV infection and immunization, especially from the vaccine point of view, should be the focus of HIV vaccine research for a long time.
References
- Guroff, M. R., Roilides, E., Muldoon, R., Venzon, D., Husson, R., Marshall, D., ... & Pizzo, P. A. (1993). Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value. Journal of Infectious Diseases, 167(3), 538-546.
- Sengupta, S., & Siliciano, R. F. (2018). Targeting the latent reservoir for HIV-1. Immunity, 48(5), 872-895.
